News

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
neither Hims & Hers nor archrival Eli Lilly can compete in. Valued at just 13 times trailing earnings, Novo Nordisk ...
Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...